One Lung Ventilation in Thoracic Surgery
Conditions
Keywords
inflammatory cytokine, protective effect, Dexmedetomidine, Precedex, one lung ventilation, ischemia-reperfusion
Brief summary
During lung surgery, mechanical one-lung ventilation is usually mandatory to provide appropriate surgical condition. However, not only mechanical ventilation is associated with inflammatory response, but also one lung ventilation will result in detrimental effects such as ischemia and reperfusion injury, and systemic inflammatory responses. Dexmedetomidine is an alpha-2 selective agonist. It was reported that dexmedetomidine decreased reperfusion injury, reduce the release of proinflammatory mediator and protected lungs from reperfusion injury in esophageal cancer patients who undergoing one lung ventilation from reducing oxidative stress metabolites. However, other details of protective effects is still unknown. High mobility group box 1 (HMGB1) is an important proinflammatory factor. It was found to be related to ventilator induced lung injury in several condition. Animal studies also showed that dexmedetomidine reduces the expression of messenger ribonucleic acid in lipopolysaccharide-activated macrophage so that decrease the amount of HMGB1 release. However, clinical trials about these are still lacking. In this study, we will investigate the protective effects of dexmedetomidine to patients undergoing video-assisted thoracoscopic surgery, especially on the specific inflammatory markers- plasma HMGB1 and other inflammatory cytokines (eg. interleukin-1. interleukin-6). This will let us to know the role of HMGB1 during one-lung ventilation injury and the effect of dexmedetomidine in regulating the release of HMGB1. This study will become a basis of further medical therapy in treating inflammation.
Interventions
DRUGDexmedetomidine
In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
DRUGPlacebo control
In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
Sponsors
National Taiwan University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. American Society of Anesthesiologists physical classification I-II patients who receive VATS lobectomy 2. Patients with the following will be excluded: * suspect of infection, eg. white blood cell count\> 10000 ; fever\> 38.3℃ * preoperative cardiac or renal dysfunction, eg. New York Heart Association \>= II, estimated glomerular filtration rate\< 60 * predisposing liver dysfunction, eg. aspartate aminotransferase or alanine aminotransferase \>100; total bilirubin\> 2mg/dl; \>= Child B liver cirrhosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative plasma level of HMGB1 | 2 days |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative complications | during hospital stay, an expected average of one week |
Other
| Measure | Time frame |
|---|---|
| Postoperative pain score | 2 days |
Countries
Taiwan
Outcome results
None listed